Skip to content 
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland. more
| Time Frame | BRNS | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -1.08% | -0.67% | -3.56% |
| 1-Month Return | -10.1% | -9.28% | -7.98% |
| 3-Month Return | -21.44% | -7.09% | -7.37% |
| 6-Month Return | -56% | 3.34% | -5.14% |
| 1-Year Return | -43.46% | -1.5% | 13.04% |
| 3-Year Return | -75.45% | 11.09% | 54.47% |
| 5-Year Return | -96.14% | 23.2% | 59.46% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 268.00K | 44.70M | 802.00K | 14.97M | - | [{"date":"2021-12-31","value":0.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.79,"profit":true},{"date":"2024-12-31","value":33.49,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Cost of Revenue | - | - | 3.11K | 5.80M | 5.86M | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":0.05,"profit":true},{"date":"2024-12-31","value":99.04,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | 268.00K | 44.70M | 802.00K | 14.97M | (5.86M) | [{"date":"2021-12-31","value":0.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.79,"profit":true},{"date":"2024-12-31","value":33.49,"profit":true},{"date":"2025-12-31","value":-13.11,"profit":false}] |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Operating Expenses | 45.49M | 48.74M | 84.72M | 82.94M | 48.34M | [{"date":"2021-12-31","value":53.7,"profit":true},{"date":"2022-12-31","value":57.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":97.9,"profit":true},{"date":"2025-12-31","value":57.06,"profit":true}] |
| Operating Income | (45.22M) | (4.04M) | (83.91M) | (67.97M) | (54.19M) | [{"date":"2021-12-31","value":-4522100000,"profit":false},{"date":"2022-12-31","value":-404100000,"profit":false},{"date":"2023-12-31","value":-8391400000,"profit":false},{"date":"2024-12-31","value":-6797000000,"profit":false},{"date":"2025-12-31","value":-5419434900,"profit":false}] |
| Total Non-Operating Income/Expense | (8.59M) | 7.97M | 10.98M | 9.37M | - | [{"date":"2021-12-31","value":-78.17,"profit":false},{"date":"2022-12-31","value":72.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":85.3,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | (51.14M) | 850.00K | (76.52M) | (61.23M) | (68.79M) | [{"date":"2021-12-31","value":-6016.47,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-9002.59,"profit":false},{"date":"2024-12-31","value":-7203.18,"profit":false},{"date":"2025-12-31","value":-8093.34,"profit":false}] |
| Income Taxes | (28.00K) | (4.47M) | (3.08M) | (44.00K) | (2.18M) | [{"date":"2021-12-31","value":-2800000,"profit":false},{"date":"2022-12-31","value":-447100000,"profit":false},{"date":"2023-12-31","value":-307500000,"profit":false},{"date":"2024-12-31","value":-4400000,"profit":false},{"date":"2025-12-31","value":-218008200,"profit":false}] |
| Income After Taxes | (51.11M) | 5.32M | (73.45M) | (61.18M) | - | [{"date":"2021-12-31","value":-960.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1380.32,"profit":false},{"date":"2024-12-31","value":-1149.84,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (51.11M) | 5.32M | (77.32M) | (61.18M) | - | [{"date":"2021-12-31","value":-960.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1453.11,"profit":false},{"date":"2024-12-31","value":-1149.84,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (50.87M) | 5.34M | (73.35M) | (61.07M) | (66.43M) | [{"date":"2021-12-31","value":-952.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1373.03,"profit":false},{"date":"2024-12-31","value":-1143.28,"profit":false},{"date":"2025-12-31","value":-1243.5,"profit":false}] |
| EPS (Diluted) | (3.05) | 0.13 | (1.92) | (1.24) | (1.64) | [{"date":"2021-12-31","value":-2346.15,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1476.92,"profit":false},{"date":"2024-12-31","value":-955.46,"profit":false},{"date":"2025-12-31","value":-1261.69,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| BRNS | |
|---|---|
| Cash Ratio | 7.03 |
| Current Ratio | 7.77 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| BRNS | |
|---|---|
| ROA (LTM) | -28.08% |
| ROE (LTM) | -65.02% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| BRNS | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.24 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.76 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| BRNS | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 2.16 |
| P/B | 0.30 |
| Price/FCF | NM |
| EV/R | 0.62 |
| EV/Ebitda | NM |
Barinthus Biotherapeutics plc (BRNS) share price today is $0.569
Yes, Indians can buy shares of Barinthus Biotherapeutics plc (BRNS) on Vested. To buy
Yes, you can purchase fractional shares of Barinthus Biotherapeutics plc (BRNS) via the Vested app. You can start investing in Barinthus Biotherapeutics plc (BRNS) with a minimum investment of $1.
You can invest in shares of Barinthus Biotherapeutics plc (BRNS) via Vested in three simple steps:
The 52-week high price of Barinthus Biotherapeutics plc (BRNS) is $2.91. The 52-week low price of Barinthus Biotherapeutics plc (BRNS) is $0.51.
The price-to-earnings (P/E) ratio of Barinthus Biotherapeutics plc (BRNS) is
The price-to-book (P/B) ratio of Barinthus Biotherapeutics plc (BRNS) is 0.30
The dividend yield of Barinthus Biotherapeutics plc (BRNS) is 0.00%
The market capitalization of Barinthus Biotherapeutics plc (BRNS) is $22.47M
The stock symbol (or ticker) of Barinthus Biotherapeutics plc is BRNS
Consider the share price of Barinthus Biotherapeutics plc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Barinthus Biotherapeutics plc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Barinthus Biotherapeutics plc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Barinthus Biotherapeutics plc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Barinthus Biotherapeutics plc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Barinthus Biotherapeutics plc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
